Related Experiment Video
Updated: Jun 28, 2026
Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
Association of Sleep-Related Hypoxemia With Survival in Patients With Non-Small Cell Lung Cancer: The NEOSAS Groupe
Grégoire Justeau1, Laurent Greillier2, Florent Vinas3
1Pneumology Department, CHU Angers, Angers, France.
Background:
OSA and its hypoxia-related consequences are associated with an increased lung cancer risk.
Research Question:
Does an association exist for OSA and sleep-related hypoxemia with increased mortality in patients with non-small cell lung cancer (NSCLC)?
Study Design And Methods:
Patients with newly diagnosed NSCLC and Eastern Cooperative Oncology Group performance status (ECOG-PS) 0 through 2 enrolled in this multicenter study (27 study sites) were administered questionnaires and a home sleep study and were followed up for 18 months. OSA was defined as a 3% oxygen desaturation index (ODI) of ≥ 16 events/h. Cox proportional hazards models were used to evaluate the association of OSA and terciles of indices of sleep-related hypoxemia (ODI, mean oxygen saturation [Spo2], and percentage of time with Spo2 of ≤ 90% [T90]) with mortality.
Results:
Of 1,201 patients with newly diagnosed NSCLC enrolled between February 2016 and December 2020, 1,001 patients with a valid sleep study were analyzed (71% male patients; mean [SD] age, 63.6 [9.7] years; 11% of stage I or II disease), and 383 patients (38%) had a diagnosis of OSA. Compared with patients without OSA, those with OSA showed no difference in sleep quality, quality of life, ECOG-PS, cancer stage at diagnosis, or survival. However, patients with severe sustained sleep-related hypoxemia were at higher risk of death (hazard ratio [HR], 1.35 [95% CI, 1.05-1.74] for T90 ≥ 35% vs < 4%; HR, 1.48 [95% CI, 1.16-1.98] for mean Spo2 < 91% vs ≥ 93%) after adjustment for confounders including ECOG-PS, cancer stage, and Spo2 with room air, and surgical treatment.
Interpretation:
Our results show that in patients with newly diagnosed NSCLC, severe nocturnal hypoxemia is associated with lower overall survival. The impact of oxygen therapy on survival deserves to be evaluated in patients with NSCLC and marked nocturnal hypoxemia.
Clinical Trial Registration:
ClinicalTrials.gov; No.: NCT02648087; URL: www.
Clinicaltrials:
gov.
Related Concept Videos
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:19Respiratory Assessment: Purpose and Indications
Objectives and Importance:
The primary goal of respiratory assessment is to evaluate patients at early risk of clinical deterioration. Since respiratory distress often precedes other signs of declining health, breathing patterns and sounds become a...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
01:23Hypoxia
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
01:21Cancer Survival Analysis